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Abstract
Background: Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is an
effective strategy to improve progression-free survival in hormone receptor-positive (HR+), human epidermal
growth factor receptor 2 (HER2)-negative advanced breast cancer. There is a lack of comparative data to help
clinicians decide if CDK4/6 inhibitors can best be added to first- or second-line endocrine therapy. Improvement in
median progression-free survival in first-line studies is larger than in second-line studies, but CDK4/6 inhibitors have
not consistently shown to improve overall survival or quality of life. They do come with added toxicity and costs,
and many patients have lasting disease remission on endocrine therapy alone. No subgroup has been identified to
select patients who are most likely to benefit from the addition of CDK4/6 inhibition in any line of treatment.
Altogether, these factors make that the optimal strategy for using CDK4/6 inhibitors in clinical practice is unknown.
Methods: The SONIA study is an investigator-initiated, multicenter, randomized phase III study in patients with HR
+/HER2-negative advanced breast cancer. Patients are randomly assigned to receive either strategy A (first-line
treatment with a non-steroidal aromatase inhibitor combined with CDK4/6 inhibition, followed on progression by
fulvestrant) or strategy B (first-line treatment with a non-steroidal aromatase inhibitor, followed on progression by
fulvestrant combined with CDK4/6 inhibition). The primary objective is to test whether strategy A is more effective
than strategy B. The primary endpoint is time from randomization to second objective progression (PFS2).
Secondary endpoints include overall survival, safety, quality of life, and cost-effectiveness. Five-hundred seventy-four
events yield 89% power to show that strategy A has statistically significant, clinically meaningful superior PFS2
(according to ESMO-MCBS) in a log-rank test at the two-sided 95% confidence level. Given an accrual period of
42 months and an additional 18 months follow-up, inclusion of 1050 evaluable patients is required.
Discussion: This study design represents daily clinical practice, and the results will aid clinicians in deciding when
adding CDK4/6 inhibitors to endocrine therapy will benefit their patients most. Additional biomarker analyses may
help to optimize patient selection.
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Background
Hormone receptor-positive (HR+), human epidermal
growth factor receptor 2 (HER2)-negative breast cancer is
the most common subset of breast cancer [1]. About
one-third of all HR+/HER2-negative patients, initially diag-
nosed with early stage disease, experience disease recur-
rence [2]. As a result, the HR+/HER2-negative subset is
responsible for the majority of breast cancer related deaths.
For decades, the mainstay treatment of HR+ advanced
breast cancer (ABC) has been sequential endocrine ther-
apies targeting the estrogen receptor-signaling pathway.
Although endocrine therapies may lead to durable dis-
ease control, the majority of patients progress during
endocrine therapy (acquired resistance) and there is also
a proportion of patients that fails to respond to initial
therapy (de novo resistance) [3].
In an effort to overcome endocrine resistance, treat-
ments with novel molecular targets have been developed,
including cyclin-dependent kinase 4 and 6 (CDK4/6) in-
hibitors. CDK4/6 inhibitors prevent cell cycle progression
from G1 into S phase [4]. Several (pre)clinical studies have
shown efficacy of combining CDK4/6 inhibitors with
endocrine therapies in HR+/HER2-negative ABC [5–9].
Currently, three CDK4/6 inhibitors have been FDA- and
EMA-approved: palbociclib, ribociclib, and abemaciclib.
In first-line setting, adding CDK4/6 inhibitors to aroma-
tase inhibitors leads to approximately doubling of
progression-free survival (PFS). The PALOMA-2 phase III
trial randomized patients between either letrozole and pal-
bociclib or letrozole and placebo. Median PFS in the
palbociclib-group was 24.8 months versus 14.5 months in
the control group (hazard ratio (HR) 0.58 (95% confidence
interval [CI]: 0.46–0.72)) [8]. The MONALEESA-2 trial
with ribociclib resulted in a median PFS in the combin-
ation group (ribociclib with letrozole) of 25.3 months ver-
sus 16.0 months in the control group (placebo with
letrozole) with an HR of 0.57 (95% confidence interval
[CI]: 0.46–0.70) [10, 12]. In the MONARCH-3 trial, abe-
maciclib was used. Median PFS was not reached in the
combination group (abemaciclib with either letrozole or
anastrozole) versus 14.7 months in the control group (pla-
cebo with either letrozole or anastrozole), with an HR of
0.54 (95% confidence interval [CI]: 0.41–0.72) [9].
Combining CDK4/6 inhibitors with fulvestrant proved to
be an effective strategy in second and subsequent treatment
lines. In the PALOMA-3 phase III trial patients whose dis-
ease had progressed after one or more previous lines of
therapy were treated with either fulvestrant and palbociclib
or fulvestrant and placebo. The PFS in the combination
group (palbociclib with fulvestrant) was 9.5 months versus
4.6 months in the control group (placebo with fulvestrant)
with an HR of 0.46 (95% confidence interval [CI]: 0.36–
0.59) [5]. The MONALEESA-3 study compared fulvestrant
with or without ribociclib in patients who were treatment
naïve or had received up to one line of prior endocrine
therapy. Median PFS increased from 12.8 months in the
fulvestrant + placebo group to 20.5 months in the fulves-
trant + ribociclib group (HR 0.59; 95% confidence interval
[CI]: 0.48-0.73) [13]. Combining abemaciclib with fulves-
trant as second-line treatment in the MONARCH-2 trial
resulted in a median PFS of 16.4 months versus 9.3 months
in the control group (placebo with fulvestrant) with an HR
of 0.55 (95% confidence interval [CI]: 0.45–0.68) [11]. Dif-
ferent from PALOMA-3, only one prior line of endocrine
therapy was allowed and no chemotherapy for metastatic
disease was allowed. This probably accounts for the differ-
ences in median PFS between both studies. The hazard ra-
tios, however, are very similar.
The above-mentioned studies have led to the firm belief
that combining CDK4/6 inhibitors with endocrine therapy
leads to an improved PFS in HR+/HER2-negative advanced
breast cancer. Remarkably, no benefit in overall survival
(OS) could be demonstrated so far. The only available ma-
ture OS data at this point arise from the preceding phase II
PALOMA-1 trial. In this study, OS was very similar with
and without palbociclib [14]. A recently published update
of the PALOMA-3 data did not show a statistically signifi-
cant overall survival benefit for the addition of palbociclib
to fulvestrant in the entire trial group [15].
Combining CDK4/6 inhibition with endocrine therapy
is associated with increased toxicity compared to endo-
crine therapy alone [5, 8–11]. Almost 70% of patients
experience CTCAE grade 3–4 toxicity with the combin-
ation compared to 20% with endocrine therapy alone.
Patients treated with combination therapy primarily ex-
perience bone marrow suppression, but may also experi-
ence fatigue, diarrhea, liver dysfunction, and QTc
prolongation. As a result, the use of CDK4/6 inhibitors
requires more frequent hospital visits and controls. The
average duration of use of CDK4/6 inhibitors is substan-
tially longer in first-line compared to second- or subse-
quent lines (approximately 25 months and 9–
16 months, respectively). This means patients are sub-
jected to potential side effects and more frequent
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hospital visits for a longer period of time when CDK4/6
inhibitors are used as a first-line treatment. This might
be part of the reason why despite the clear benefit in
PFS, adding a CDK4/6 inhibitor to endocrine therapy to
first-line treatment does not clearly result in improved
quality of life (QoL). Health-related QoL, as assessed by
validated questionnaires, did not differ between treat-
ment arms in the PALOMA-2 and MONALEESA-2 trial
[16, 17]. The effect of CDK4/6 inhibition is consistent
across a wide range of subgroups based on clinical and
pathological characteristics. As a consequence, no pre-
dictive biomarkers exist to select patients who are most
likely to benefit from the addition of CDK4/6 inhibition.
In summary, it is currently not known which treat-
ment strategy for deploying CDK4/6 inhibitors will
benefit patients most. Adding CDK4/6 inhibitors in first-
compared to second-line endocrine treatment may pro-
vide longer PFS benefit but is associated with longer use
of the drugs, resulting in more toxicity and costs, with-
out clear benefit on OS and QoL [18]. The aim of this
project is to evaluate whether the sequence of an AI plus
CDK4/6 inhibition in first-line followed by fulvestrant in
second-line (strategy A) is superior to the sequence of
an AI in first-line followed by fulvestrant plus CDK4/6
inhibition in second-line (strategy B).
Methods/design
The SONIA study is an investigator-initiated nation-
wide, multicenter, randomized phase III study in
women with HR+/HER2-negative advanced breast
cancer who have not received any prior systemic
anti-cancer therapy for advanced disease. Patients are
randomly assigned to receive either strategy A (first--
line treatment with a non-steroidal aromatase inhibi-
tor combined with CDK4/6 inhibition, followed on
progression by fulvestrant) or strategy B (first-line
treatment with a non-steroidal aromatase inhibitor,
followed on progression by fulvestrant combined with
CDK4/6 inhibition). A schematic overview of the
study design is shown in Fig. 1.
Objectives
The primary objective is to test whether CDK4/6 inhib-
ition added to the non-steroidal aromatase inhibitor in
first-line treatment (strategy A) is more effective than
addition of CDK4/6 inhibition to fulvestrant in
second-line treatment (strategy B). The primary end-
point is progression-free survival after two lines (PFS2),
defined as time from randomization until objective dis-
ease progression, symptomatic deterioration, or initi-
ation of a new therapeutic agent on second-line
treatment, death, or progression during a break in initial
therapy and without further therapy within one month,
whichever occurs first. When a patient dies while on
first-line treatment or is ineligible to continue to
second-line endocrine treatment according to protocol,
her PFS2 equals her PFS1. Secondary objectives include
comparisons of OS, QoL, safety and tolerability, object-
ive response rate (ORR) and cost-effectiveness. Add-
itional biomarker analyses are planned, involving
pharmacokinetics and pharmacogenetics analyses as well
as baseline, on-treatment and on-progression tumor bi-
opsies, liquid biopsies and nuclear imaging; patients are
required to provide additional informed consent for
these procedures.
Inclusion criteria
Eligible patients have histologically or cytologically
proven diagnosis of adenocarcinoma of the breast with
evidence of locoregional recurrent or metastatic disease
and will be candidates to receive non-steroidal AIs as
first-line treatment for their advanced disease. Patients
are not candidates for curative therapies and may not
have received any prior systemic anticancer therapies for
metastatic disease other than a maximum of 28 days of
palliative endocrine treatment. (Neo)adjuvant aromatase
inhibitor use is allowed, provided that the disease did
not progress while on or within 12 months from ending
treatment. Patients must have measurable or evaluable
disease as per RECIST 1.1 [19]. Bone lesions visible on
bone scan or fludeoxyglucose positron emission
Fig. 1 Schematic overview of study design. Non-steroidal AI: non-steroidal aromatase-inhibitor, either letrozole or anastrozole (at the discretion of
the treating physician). CDK4/6 inhibitor: type of CDK4/6 inhibitor according to physician’s choice and reimbursement policies
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tomography (FDG PET) should be confirmed by com-
puted tomography (CT) or magnetic resonance imaging
(MRI) at baseline. The patient or a legal representative
must be able and willing to give informed consent.
Exclusion criteria
Patients are excluded from this study in case of ad-
vanced, symptomatic, visceral spread with the risk of
life-threatening complications in the short term and in
case of known active uncontrolled or symptomatic me-
tastases of the central nervous system (including lepto-
meningeal disease). Patients who are currently being
treated with strong cytochrome P450 3A4 (CYP3A4) in-
ducers or inhibitors or were previously treated with
CDK4/6 inhibitors, are not amenable for study participa-
tion. Other conditions excluding a patient from partici-
pating are other malignancies (except those that are not
believed to influence the patient’s prognosis and do not
require any further treatment), prolonged QTc time (>
480 ms), bowel disease interfering with the uptake of
oral medication, or any other medical condition that in-
terferes with study procedures or compliance.
Interventions
Patients will be randomized in a 1:1 ratio to receive ei-
ther strategy A or strategy B. Patients randomized to
strategy A will receive first line treatment with letrozole
2.5 mg once daily or anastrozole 1 mg once daily con-
tinuously in combination with either palbociclib 125 mg
once daily or ribociclib 600 mg once daily on day 1–21
of every 28-day cycle. Second-line treatment will consist
of fulvestrant 500 mg on day 1, day 15 and day 29 of the
first month and monthly thereafter. Patients randomized
to strategy B will receive letrozole 2.5 mg once daily or
anastrozole 1 mg once daily continuously as first-line
treatment. Second-line treatment will consist of fulves-
trant 500 mg on day 1, day 15 and day 29 of the first
month and monthly thereafter in combination with pal-
bociclib 125 mg once daily on day 1–21 of every
28-day cycle. The proposed study design will be
amended upon reimbursement to allow ribociclib also in
strategy B and abemaciclib as third alternative CDK4/6
inhibitor. Patients will be stratified by site of disease (vis-
ceral versus non-visceral), prior endocrine treatment in
(neo) adjuvant setting (yes versus no), hospital, and type
of CDK4/6 inhibitor. All pre- and perimenopausal
women will also receive ovarian ablation or suppression.
Patients will continue to receive the assigned study
medication until objective disease progression, symp-
tomatic deterioration, or unacceptable toxicity (at the
discretion of the treating physician), death, or with-
drawal of consent, whichever occurs first. Patients will
be screened at baseline for eligibility, and after signing
informed consent, baseline measurements will be
obtained. Subsequently, patients will be followed up ac-
cording to their treatment group. Patients randomized
to strategy A will undergo laboratory evaluation after 2,
4, 6, and 8 weeks and monthly thereafter. Patients ran-
domized to strategy B will undergo laboratory evaluation
three-monthly during first-line treatment. During
second-line treatment, the follow-up schedule for pa-
tients in group A will be identical to that of patients in
group B during first-line treatment and vice versa. In
both treatment arms, response assessment and safety
evaluation will be performed every three months by
means of imaging, laboratory evaluation, evaluation of
ECOG performance status, physical examination, and re-
cording of adverse events and concomitant medication.
Questionnaires regarding QoL and cost-effectiveness will
be administered at several prespecified time points in the
study. A table with all study-related activities can be found
in Additional file 1.
Dose modifications
Every effort should be made to administer study treat-
ment on the planned dose and schedule. However, in the
event of significant treatment-related toxicity, adminis-
tration of CDK4/6 inhibitors may need to be adjusted.
Dose adjustment is not permitted for non-steroidal AIs,
fulvestrant or LHRH agonists. Depending on the nature
of the toxicity observed, treatment interruption of
CDK4/6 inhibitors may be required. Treatment with
letrozole/anastrozole or fulvestrant will continue as
pre-planned. For more information about dose modifica-
tions, see Additional file 2.
Concomitant treatment
Standard therapies for pre-existing medical conditions,
medical and/or surgical complications, and palliation are
allowed during study participation. Palliative radiother-
apy is allowed during the study, although it is recom-
mended to initiate radiotherapy before study initiation if
possible. Caution is advised on theoretical grounds for
any surgical procedures during the study. The appropri-
ate interval of time between surgery and CDK4/6 inhibi-
tors required to minimize the risk of impaired wound
healing and bleeding has not been determined. Medica-
tions not allowed during study participation include
other anticancer agents, strong CYP3A4 inhibitors or in-
ducers, hormone replacement therapy and hormonal
contraception.
Statistics: Sample size and power calculations
The primary outcome for this study is PFS2, defined as
time from randomization to second objective progres-
sion. The threshold for a clinically relevant difference in
PFS2 is set according to the European Society for Med-
ical Oncology - Magnitude of Clinical Benefit Scale
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(ESMO-MCBS) [20]. The maximal preliminary score for
efficacy based on PFS is 3 out of 4, with a higher score
indicating more clinical benefit (see Table 1). The pre-
liminary scores can be upgraded or downgraded depend-
ing on data on toxicity and quality of life to achieve the
final score.
Based on the PALOMA-studies, we estimated strategy
A to show a median PFS2 of 31 months and strategy B
to show a median PFS2 of 28 months, with a corre-
sponding hazard ratio of 0.85. For strategy A to be pref-
erable according to ESMO-MCBS, a statistically
significant difference in PFS of at least three months and
a lower limit of the 95% confidence interval ≤ 0.65 for
the corresponding hazard ratio is required. In the power
calculation we implemented these minimum require-
ments by multiplying the estimated hazards in the pal-
bociclib + letrozole group (PALOMA-2) and in the
palbociclib + fulvestrant group (PALOMA-3) by 0.88
while multiplying the estimated hazards in the letrozole
single agent group (PALOMA-2) and fulvestrant single
agent group (PALOMA-3) by 1/0.88. This modification
of the actual hazards yields expected median PFS2 times
of 32.6 and 27.4 months in the strategy A and strategy
B, respectively.
Based on 10,000 simulated trials with the modified
hazards we conclude that inclusion of 500 patients per
arm in a period of 42 months and an additional
18 months follow-up will yield an expected number of
574 events and 89% power to show that strategy A has
statistically significant superior PFS2 in a log-rank test at
the two-sided 95% confidence level. The corresponding
hazard ratio for strategy A: strategy B is 0.765 (95% CI
0.648–0.902) and the probability of meeting the
above-mentioned ESMO-MCBS criteria is 52%. If the
study fails to detect superiority, non-inferiority will be
tested next. According to the closed test principle, hier-
archical testing of superiority and non-inferiority does
not affect sample size or power of the analyses.
Statistics: Analysis
Efficacy
The difference in PFS2 (primary endpoint) will be esti-
mated using the intention-to-treat (ITT) population in a
Cox proportional hazards model accounting for all
stratification factors. An adjusted hazard ratio with a
symmetric 1-α confidence interval will be produced.
Secondary objectives include comparisons of OS,
ORR, QoL, safety and tolerability and cost-effectiveness.
A stratified log-rank test (using the same stratification
factors as for the PFS analysis) will be used to compare
OS between the treatment strategies. The ORR on each
randomized treatment strategy will be estimated by div-
iding the number of patients with objective response (ei-
ther complete response (CR) or partial response (PR)
according to RECIST 1.1) by the number of patients ran-
domized to the respective treatment strategy (“response
rate”). A 95% CI for the response rates will be provided.
Response rate comparisons between the two treatment
strategies as randomized will be assessed using
Cochran-Mantel-Haenszel (CMH) test with the same
stratification factors as for the PFS analysis. Analyses of
ORR will be performed on the ITT population. Health
related QoL will be analyzed using patient reported out-
comes of the disease specific FACT-B and generic
EQ-5D-5 L questionnaires [21, 22] (https://euroqol.org/
eq-5d-instruments/eq-5d-5l-about/). The FACT-B and
EQ-5D scoring guidelines will be used to compute
FACT module specific scores, overall FACT-B quality of
life scores, and EQ-5D utility scores. The cost and out-
comes of both arms will be assessed by Mann Whitney
test. Cost-effectiveness will be determined by comparing
costs and effects of both treatment strategies by means
of the Institute for Medical Technology Assessment Re-
source Use Questionnaire Borstkanker (iMTA-RUQ-B).
This questionnaire was developed by iMTA by combin-
ing questions from the iMTA Productivity Cost Ques-
tionnaire (iPCQ), the iMTA Medical Consumption
Questionnaire (iMCQ) and the iMTA Valuation of Infor-
mal Care Questionnaire (iVICQ) (https://www.imta.nl/
questionnaires/) [23]. Quality adjusted life years (QALY)
will be computed by multiplying life-years with the ob-
served utility scores during those life years. As a societal
perspective will be taken into account all relevant direct
and indirect costs will be measured. In this respect, the
friction cost method will be used for estimating the soci-
etal costs of productivity losses.
Compliance
It is conceivable that patients upon first progression will
not proceed to the second phase of the study but instead
start a different treatment. While this will not prevent us
to analyze their data (for these patients the PFS2 will be
considered equal to the PFS1), a large fraction of pa-
tients deviating from protocol will nevertheless devaluate
the results of the study, as it then answers a different
question than was originally asked. Based on simula-
tions, the change in the observed hazard ratio compar-
ing PFS2 in both treatment arms can exceed 0.05 when
> 15% of patients are non-compliant in their second line
treatment. Therefore, we will do an interim analysis for
Table 1 preliminary magnitude of clinical benefit grade based
on PFS
Grade 3 HR ≤0.65 and gain ≥3 months
Grade 2 HR ≤0.65 but gain < 3 months
Grade 1 HR > 0.65
PFS progression-free survival, HR hazard ratio (thresholds refer to the lower
extreme of the 95% confidence interval)
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compliance, where we stop inclusion into the study early
when more than 15% of patients that had progression in
first-line did not go on to second-line according to
protocol. This evaluation will be carried out at the mo-
ment that 100 patients in arm A had a PFS1 event. If the
study is stopped at that moment, all patients already in
the study (expected to be around 670) will be followed
until PFS2 and analyzed according to protocol.
Safety
The As Treated (AT) population will be the primary
population for safety evaluation. Summaries of adverse
events and other safety parameters will be provided as
appropriate. The study will use a Data Safety and Moni-
toring Board (DSMB). The DSMB will be responsible for
ongoing monitoring of the safety of patients in the study.
The DSMB will make a recommendation as to whether
or not the study should continue based on ongoing re-
views of safety data.
Legislation and logistics
The SONIA study was approved by the accredited Med-
ical Ethics Committee of the Netherlands Cancer Insti-
tute – Antoni van Leeuwenhoek (METC AVL) on
September 29th, 2017. The study will be conducted in
accordance with legal and regulatory requirements, as
well as the general principles set forth in the Inter-
national Ethical Guidelines for Biomedical Research In-
volving Human Subjects, Guidelines for good Clinical
Practice (GCP), and the Declaration of Helsinki. A total
of 74 hospitals in the Netherlands will participate. Pa-
tients will be informed about the study and asked to par-
ticipate by their treating physician.
A centralized internet/telephone registration system
(ALEA) is used for randomization. All data will be re-
corded by qualified data managers in an electronic case
report form (eCRF), which is managed by “Borstkanker
Onderzoekgroep” (BOOG), the sponsor of this study.
On site monitoring will take place conform the guideline
of the “Nederlandse Federatie van Universitaire Medisch
Centra” (NFU) called “Kwaliteitsborging van mensge-
bonden onderzoek 2012” by the appointed monitor.
Discussion
The SONIA study aims to determine the optimal pos-
ition of addition of CDK4/6 inhibitors to standard endo-
crine treatment in patients with advanced, HR
+/HER2-negative breast cancer by evaluating its efficacy,
safety, quality of life and cost-effectiveness in first-line
compared to second-line treatment. The study is de-
signed to reflect daily clinical practice and is in line with
current treatment guidelines [24, 25].
PFS2 was selected as a primary outcome, since it will
be readily available and is the best available surrogate for
OS [26]. Because all patients in our study will have re-
ceived CDK4/6 inhibitors (either in first- or in
second-line) when they reach the end of the study, our
results will not be confounded by post-trial therapy with
the investigational drug. Secondary outcomes include
OS (historically the most unambiguous efficacy marker
[27]), QoL (an important patient-reported outcome
measure) and cost-effectiveness. In addition, we are
planning to perform biomarker analyses, which may
contribute to current knowledge on determining which
patients will or will not benefit from the addition of
CDK4/6 inhibition to standard endocrine treatment.
Trial status: we are currently recruiting patients.
Additional files
Additional file 1: Summary of study-related activities (DOCX 308 kb)
Additional file 2: Summary of recommendations regarding dose
modifications (DOCX 19 kb)
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